205 related articles for article (PubMed ID: 25936222)
1. Linifanib: current status and future potential in cancer therapy.
Aversa C; Leone F; Zucchini G; Serini G; Geuna E; Milani A; Valdembri D; Martinello R; Montemurro F
Expert Rev Anticancer Ther; 2015 Jun; 15(6):677-87. PubMed ID: 25936222
[TBL] [Abstract][Full Text] [Related]
2. A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.
Luo Y; Jiang F; Cole TB; Hradil VP; Reuter D; Chakravartty A; Albert DH; Davidsen SK; Cox BF; McKeegan EM; Fox GB
Cancer Chemother Pharmacol; 2012 Apr; 69(4):911-21. PubMed ID: 22080168
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS.
Chan E; Goff LW; Cardin DB; Ancell K; Smith SJ; Whisenant JG; Ye F; Berlin JD
Invest New Drugs; 2017 Aug; 35(4):491-498. PubMed ID: 28353122
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.
Toh HC; Chen PJ; Carr BI; Knox JJ; Gill S; Ansell P; McKeegan EM; Dowell B; Pedersen M; Qin Q; Qian J; Scappaticci FA; Ricker JL; Carlson DM; Yong WP
Cancer; 2013 Jan; 119(2):380-7. PubMed ID: 22833179
[TBL] [Abstract][Full Text] [Related]
5. Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib.
Xiong H; Chiu YL; Ricker JL; LoRusso P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):55-61. PubMed ID: 24810181
[TBL] [Abstract][Full Text] [Related]
6. Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.
Franklin PH; Banfor PN; Tapang P; Segreti JA; Widomski DL; Larson KJ; Noonan WT; Gintant GA; Davidsen SK; Albert DH; Fryer RM; Cox BF
J Pharmacol Exp Ther; 2009 Jun; 329(3):928-37. PubMed ID: 19255283
[TBL] [Abstract][Full Text] [Related]
7. Linifanib.
Drugs R D; 2010; 10(2):111-22. PubMed ID: 20698720
[TBL] [Abstract][Full Text] [Related]
8. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Cainap C; Qin S; Huang WT; Chung IJ; Pan H; Cheng Y; Kudo M; Kang YK; Chen PJ; Toh HC; Gorbunova V; Eskens FA; Qian J; McKee MD; Ricker JL; Carlson DM; El-Nowiem S
J Clin Oncol; 2015 Jan; 33(2):172-9. PubMed ID: 25488963
[TBL] [Abstract][Full Text] [Related]
9. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.
Asahina H; Tamura Y; Nokihara H; Yamamoto N; Seki Y; Shibata T; Goto Y; Tanioka M; Yamada Y; Coates A; Chiu YL; Li X; Pradhan R; Ansell PJ; McKeegan EM; McKee MD; Carlson DM; Tamura T
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1477-86. PubMed ID: 22382879
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Horinouchi H; Yamamoto N; Nokihara H; Horai T; Nishio M; Ohyanagi F; Horiike A; Nakagawa K; Terashima M; Okabe T; Kaneda H; McKee MD; Carlson DM; Xiong H; Tamura T
Cancer Chemother Pharmacol; 2014 Jul; 74(1):37-43. PubMed ID: 24807459
[TBL] [Abstract][Full Text] [Related]
11. Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma.
Chiu YL; Carlson DM; Pradhan RS; Ricker JL
Clin Ther; 2013 Nov; 35(11):1770-7. PubMed ID: 24094464
[TBL] [Abstract][Full Text] [Related]
12. Murine colitis treated with multitargeted tyrosine kinase inhibitors.
Knod JL; Crawford K; Dusing M; Frischer JS
J Surg Res; 2016 Feb; 200(2):501-7. PubMed ID: 26521099
[TBL] [Abstract][Full Text] [Related]
13. Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors.
Kircher SM; Nimeiri HS; Benson AB
Cancer J; 2016; 22(3):182-9. PubMed ID: 27341596
[TBL] [Abstract][Full Text] [Related]
14. Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients.
Salem AH; Koenig D; Carlson D
Clin Pharmacokinet; 2014 Apr; 53(4):347-59. PubMed ID: 24307488
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model.
Mudd SR; Voorbach MJ; Reuter DR; Tapang P; Hickson JA; Refici-Buhr M; Fox GB; Albert DH; Luo Y; Day M
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1669-72. PubMed ID: 22327787
[TBL] [Abstract][Full Text] [Related]
16. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
Zhou J; Goh BC; Albert DH; Chen CS
J Hematol Oncol; 2009 Jul; 2():33. PubMed ID: 19642998
[TBL] [Abstract][Full Text] [Related]
17. Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy.
Ji S; Zheng Y; Shao G; Zhou Y; Liu S
Theranostics; 2013; 3(11):816-30. PubMed ID: 24312152
[TBL] [Abstract][Full Text] [Related]
18. Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.
Hsu HW; de Necochea-Campion R; Williams V; Duerksen-Hughes PJ; Simental AA; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jul; 50(7):662-9. PubMed ID: 24735547
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
Papadimitriou M; Papadimitriou CA
Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
[TBL] [Abstract][Full Text] [Related]
20. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
